162 related articles for article (PubMed ID: 25271142)
1. Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.
Muram D; Kaltenboeck A; Boytsov N; Hayes-Larson E; Ivanova J; Birnbaum HG; Swindle R
Am J Mens Health; 2015 Nov; 9(6):496-505. PubMed ID: 25271142
[TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment patterns of testosterone replacement medications.
Donatucci C; Cui Z; Fang Y; Muram D
J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
[TBL] [Abstract][Full Text] [Related]
4. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
Schoenfeld MJ; Shortridge E; Cui Z; Muram D
J Sex Med; 2013 May; 10(5):1401-9. PubMed ID: 23464534
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
[TBL] [Abstract][Full Text] [Related]
6. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
Taylor F; Levine L
J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
[TBL] [Abstract][Full Text] [Related]
7. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.
Strollo F; Strollo G; Morè M; Magni P; Macchi C; Masini MA; Carucci I; Celotti F; Ruscica M; Gentile S
Aging Male; 2013 Jun; 16(2):33-7. PubMed ID: 23517433
[TBL] [Abstract][Full Text] [Related]
8. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
9. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
10. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
12. Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan.
Shortridge EF; Polzer P; Donga P; Wade RL
Int J Clin Pract; 2015 Jul; 69(7):783-90. PubMed ID: 25854747
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
14. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
Burns PR; Kim ED; Ruff DD; Seftel AD
Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems.
Bhatia R; Murphy AB; Raper JL; Chamie G; Kitahata MM; Drozd DR; Mayer K; Napravnik S; Moore R; Achenbach C;
AIDS; 2015 Jan; 29(1):77-81. PubMed ID: 25387318
[TBL] [Abstract][Full Text] [Related]
17. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
18. The appropriateness and persistence of testosterone replacement therapy in Ontario.
Martins D; Yao Z; Tadrous M; Shah BR; Juurlink DN; Mamdani MM; Gomes T;
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):119-126. PubMed ID: 27528454
[TBL] [Abstract][Full Text] [Related]
19. Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System.
Anderson JL; May HT; Lappé DL; Bair T; Le V; Carlquist JF; Muhlestein JB
Am J Cardiol; 2016 Mar; 117(5):794-9. PubMed ID: 26772440
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
